Liraglutide's extended 9-hour half-life is driven by albumin binding, not lymphatic absorption — lymphatic uptake was less than 0.5% of the dose for both liraglutide and exenatide.
<0.5% lymphatic uptakeDespite its fatty acid modification, liraglutide showed minimal lymphatic absorption, similar to non-lipidated exenatide
What the researchers found
After subcutaneous injection in rats:
- Liraglutide: apparent half-life 9.1 hours, delayed peak plasma levels, bioavailability ~10%
- Exenatide: half-life ~1 hour, bioavailability ~100%
Lymphatic uptake was low for both peptides (<0.5% of dose), though lymph-to-plasma concentration ratios exceeded 1 at several early timepoints, suggesting some direct lymph uptake. The single-chain C16 palmitic acid on liraglutide did not substantially boost lymphatic transport.
The authors suggest that if lymphatic delivery is desired, more lipophilic conjugates (like diacylglycerols) with higher albumin or lipoprotein binding would be needed.
Why it matters
Lipidation is widely used to extend peptide drug half-lives, but the mechanism has been debated. Is it mainly albumin binding, or does lymphatic transport play a role? This study shows that a single C16 fatty acid (like on liraglutide) does not substantially boost lymphatic uptake. This has implications for designing the next generation of long-acting peptide drugs.
The numbers in context
- Liraglutide half-life: 9.1 hours vs exenatide 1 hour
- Liraglutide bioavailability: ~10% vs exenatide ~100%
- Lymphatic uptake: <0.5% of dose for both
- Lymph:plasma ratio >1 at early timepoints
- Liraglutide lipid: single C16 palmitic acid chain
How the study worked
Pharmacokinetic study in rats comparing subcutaneous administration of liraglutide (lipidated GLP-1 agonist) and exenatide (non-lipidated GLP-1 agonist). Measured plasma concentrations, lymph concentrations, lymph-to-plasma ratios, apparent half-lives, and bioavailability. Lymph was collected via thoracic lymph duct cannulation.
Who was studied
Male rats with thoracic lymph duct cannulation for pharmacokinetic analysis
What this study cannot tell us
Tested in rats only. Rat lymphatic physiology differs from humans. The thoracic duct cannulation procedure itself may alter lymphatic flow. Only two peptides were compared. The C16 palmitic acid on liraglutide is a relatively modest lipid modification. More lipophilic conjugates might show different lymphatic behavior.
How to read the evidence
Rated moderate: well-designed pharmacokinetic study in rats with thoracic duct cannulation, though results may differ in humans.
When this study was published
Published in 2024. Settles a longstanding question about how lipidation extends peptide drug duration.
The bigger picture
Understanding why lipidated peptides last longer in the body guides the design of next-generation long-acting peptide drugs. This study clarifies that albumin binding, not lymphatic absorption, is the key mechanism.
Questions still open
- Why does liraglutide have only ~10% bioavailability despite albumin binding?
- Would optimizing the fatty acid chain improve bioavailability?
Common questions
Why does liraglutide last longer than exenatide?
What is lipidation?
Read the original research
Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 200, 114339
Citation
Reddiar, Sanjeevini Babu; Abdallah, Mohammad; Styles, Ian K; Müllertz, Olivia O; Trevaskis, Natalie L. (2024). Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 200, 114339. https://doi.org/10.1016/j.ejpb.2024.114339